Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins.
anticoagulants
biosimilarity
bovine
heparin
ovine
porcine
Journal
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
ISSN: 1938-2723
Titre abrégé: Clin Appl Thromb Hemost
Pays: United States
ID NLM: 9508125
Informations de publication
Date de publication:
Historique:
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
12
5
2020
Statut:
ppublish
Résumé
Unfractionated heparin is the first anticoagulant drug and has been successfully used clinically for over 80 years. Heparin and its analogues are used during surgery and dialysis and are often used to coat indwelling catheters and other devices where the vascular system is exposed. Most of the heparins used clinically are derived from porcine intestinal mucosa. However, heparins have also been manufactured from tissues of other mammalian species such as cows and sheep. Recently there have been attempts to generate bioengineered heparin in order to overcome contamination and antigenicity problems. Currently there are some concerns about the shortage of the porcine heparins as they are widely used in the manufacturing of the low-molecular-weight heparins. Moreover, due to cultural and religious reasons in some countries, alternative sources of heparins are needed. The Food and Drug Administration and other regulatory agencies have considered alternative sourcing of heparin for potential substitution of porcine heparin and are currently reviewing this matter. Numerous studies are ongoing to understand the structure-activity relationships of these various heparins. In this article, heparins from different animal sources were studied to determine the extent of biosimilarity between them. For these investigations, 10 batches each of bovine mucosal heparin (BMH), ovine mucosal heparin (OMH), and porcine mucosal heparin (PMH) were studied. These studies have demonstrated that OMH and PMH have comparable anticoagulant and antiproteases activities. However, BMH exhibited somewhat a lower potency compared to OMH and PMH in functional assays.
Identifiants
pubmed: 31793333
doi: 10.1177/1076029619889406
pmc: PMC7019494
doi:
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1076029619889406Références
Semin Thromb Hemost. 1999;25 Suppl 3:5-16
pubmed: 10549711
J Biol Chem. 1992 Dec 5;267(34):24347-55
pubmed: 1332952
Anal Chem. 2015 Aug 18;87(16):8275-83
pubmed: 26189325
Dev Biol Stand. 1999;99:41-4
pubmed: 10404874
Nat Biotechnol. 2016 Jun 9;34(6):625-30
pubmed: 27281424
Semin Thromb Hemost. 1985 Apr;11(2):112-20
pubmed: 3898369
Semin Thromb Hemost. 1985 Apr;11(2):176-89
pubmed: 4035365
Molecules. 2015 Mar 19;20(3):5085-98
pubmed: 25808152
Thromb Haemost. 2000 Dec;84(6):1052-6
pubmed: 11154113
Biochem Biophys Res Commun. 1974 Mar 25;57(2):488-93
pubmed: 4829406
J Pharm Sci. 2015 Feb;104(2):457-63
pubmed: 25186630
Br J Haematol. 2008 Jun;141(6):757-63
pubmed: 18355382
Nat Prod Rep. 2009 Mar;26(3):313-21
pubmed: 19240943
Thromb Res. 1985 Apr 1;38(1):11-20
pubmed: 4002198
Glycobiology. 2011 Jan;21(1):13-22
pubmed: 20729345
J Pharm Sci. 2013 May;102(5):1447-57
pubmed: 23526651
J Pharm Biomed Anal. 2018 Feb 5;149:114-119
pubmed: 29112899